Brind.

Gossamer Bio and Chiesi announced a joint collaboration to develop seralutinib under global collaboration.

2 reports, 1 independent Updated Aug 6
Gone quiet
Reports
2
Developments
2
Repetition
50%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Gossamer Bio and Chiesi announced a joint collaboration to develop seralutinib under global collaboration.

Who's involved

What this event is mainly about
Gossamer Bio (United States)Chiesi

How it developed

Newest first. Tap a step to see who reported it.
  1. Gossamer Bio submitted a New Drug Application (NDA) for its seralutinib treatment.Sub-event
  2. Gossamer Bio and Chiesi are collaborating on the development of seralutinib.1 source

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped
  • Business WireGossamer Bio Announces Second Quarter 2025 Financial Results and Provides Business Update - Topline Results from PROSERA Phase 3 Expected in February 2026 - - First Site Activations for Planned Regis
  • Unknown outlet